Robert James Glynn, Sc.D., Ph.D.
Co-Author
This page shows the publications co-authored by Robert Glynn and Sebastian Schneeweiss.
Connection Strength
15.726
-
Real-World Data Analytics Fit for Regulatory Decision-Making. Am J Law Med. 2018 May; 44(2-3):197-217.
Score: 0.759
-
Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf. 2012 May; 21 Suppl 2:138-47.
Score: 0.501
-
Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007 Oct; 45(10 Supl 2):S131-42.
Score: 0.364
-
Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction. Am J Manag Care. 2007 Aug; 13(8):445-52.
Score: 0.360
-
Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation. 2007 Apr 24; 115(16):2128-35.
Score: 0.352
-
Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization data. J Gen Intern Med. 2004 May; 19(5 Pt 1):444-50.
Score: 0.288
-
Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther. 2003 Oct; 74(4):388-400.
Score: 0.276
-
Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res. 2003 Aug; 38(4):1103-20.
Score: 0.273
-
Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance. J Clin Epidemiol. 2002 Aug; 55(8):833-41.
Score: 0.255
-
Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Obes Metab. 2022 03; 24(3):442-454.
Score: 0.243
-
Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001 Nov 01; 154(9):854-64.
Score: 0.242
-
Longitudinal Data Discontinuity in Electronic Health Records and Consequences for Medication Effectiveness Studies. Clin Pharmacol Ther. 2022 01; 111(1):243-251.
Score: 0.240
-
Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation : A Cohort Study. Ann Intern Med. 2021 09; 174(9):1214-1223.
Score: 0.237
-
Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19. Clin Pharmacol Ther. 2021 04; 109(4):816-828.
Score: 0.231
-
Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation. 2021 03 09; 143(10):1002-1013.
Score: 0.228
-
Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis. Clin Pharmacol Ther. 2020 10; 108(4):874-884.
Score: 0.219
-
Measuring Frailty in Administrative Claims Data: Comparative Performance of Four Claims-Based Frailty Measures in the U.S. Medicare Data. J Gerontol A Biol Sci Med Sci. 2020 05 22; 75(6):1120-1125.
Score: 0.219
-
Kim et al. Respond to "Estimation With Claims-Based Frailty Indexes". Am J Epidemiol. 2020 05 05; 189(5):373-374.
Score: 0.218
-
Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials. Clin Pharmacol Ther. 2020 04; 107(4):735-737.
Score: 0.215
-
External Validation of an Algorithm to Identify Patients with High Data-Completeness in Electronic Health Records for Comparative Effectiveness Research. Clin Epidemiol. 2020; 12:133-141.
Score: 0.214
-
Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. Clin Pharmacol Ther. 2020 04; 107(4):817-826.
Score: 0.210
-
Comparison of alternative approaches to trim subjects in the tails of the propensity score distribution. Pharmacoepidemiol Drug Saf. 2019 10; 28(10):1290-1298.
Score: 0.207
-
Validation of a Claims-Based Frailty Index Against Physical Performance and Adverse Health Outcomes in the Health and Retirement Study. J Gerontol A Biol Sci Med Sci. 2019 07 12; 74(8):1271-1276.
Score: 0.206
-
Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making. Clin Pharmacol Ther. 2019 04; 105(4):867-877.
Score: 0.201
-
Comparing Approaches to Measure Frailty in Medicare Data: Deficit-Accumulation Frailty Index Versus Phenotypic Frailty. J Gerontol A Biol Sci Med Sci. 2018 06 14; 73(7):989-990.
Score: 0.191
-
Out-of-system Care and Recording of Patient Characteristics Critical for Comparative Effectiveness Research. Epidemiology. 2018 05; 29(3):356-363.
Score: 0.190
-
Identifying Patients With High Data Completeness to Improve Validity of Comparative Effectiveness Research in Electronic Health Records Data. Clin Pharmacol Ther. 2018 05; 103(5):899-905.
Score: 0.183
-
Prediction Score for Anticoagulation Control Quality Among Older Adults. J Am Heart Assoc. 2017 Oct 05; 6(10).
Score: 0.182
-
Variable Selection for Confounding Adjustment in High-dimensional Covariate Spaces When Analyzing Healthcare Databases. Epidemiology. 2017 03; 28(2):237-248.
Score: 0.175
-
Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications. J Clin Epidemiol. 2016 08; 76:200-8.
Score: 0.163
-
Regularized Regression Versus the High-Dimensional Propensity Score for Confounding Adjustment in Secondary Database Analyses. Am J Epidemiol. 2015 Oct 01; 182(7):651-9.
Score: 0.157
-
Evaluating possible confounding by prescriber in comparative effectiveness research. Epidemiology. 2015 Mar; 26(2):238-41.
Score: 0.152
-
Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. Am J Med. 2015 May; 128(5):539.e7-17.
Score: 0.150
-
Studies with many covariates and few outcomes: selecting covariates and implementing propensity-score-based confounding adjustments. Epidemiology. 2014 Mar; 25(2):268-78.
Score: 0.142
-
Sequential value-of-information assessment for prospective drug safety monitoring using claims databases: the comparative safety of prasugrel v. clopidogrel. Med Decis Making. 2013 10; 33(7):949-60.
Score: 0.137
-
Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings. J Am Heart Assoc. 2013 Jul 30; 2(4):e000208.
Score: 0.136
-
Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations. Epidemiology. 2013 May; 24(3):375-8.
Score: 0.134
-
Matching by propensity score in cohort studies with three treatment groups. Epidemiology. 2013 May; 24(3):401-9.
Score: 0.134
-
Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol. 2012 Nov 26; 12:180.
Score: 0.130
-
Bias in comparative effectiveness studies due to regional variation in medical practice intensity: a legitimate concern, or much ado about nothing? Circ Cardiovasc Qual Outcomes. 2012 Sep 01; 5(5):e61-4.
Score: 0.128
-
Association between the Part D coverage gap and adverse health outcomes. J Am Geriatr Soc. 2012 Aug; 60(8):1408-17.
Score: 0.127
-
Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. Clin Pharmacol Ther. 2012 Jul; 92(1):80-6.
Score: 0.126
-
One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012 May; 21 Suppl 2:69-80.
Score: 0.125
-
Beneficiaries with cardiovascular disease and thePart D coverage gap. Circ Cardiovasc Qual Outcomes. 2012 May; 5(3):387-95.
Score: 0.125
-
Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology. 2012 Mar; 23(2):238-46.
Score: 0.124
-
Medicare part D's impact on antipsychotic drug use and costs among elderly patients without prior drug insurance. J Clin Psychopharmacol. 2012 Feb; 32(1):3-10.
Score: 0.123
-
Response to commentary by Marcus and Gibbons. Pharmacoepidemiol Drug Saf. 2012 Jul; 21(7):713.
Score: 0.123
-
An event-based approach for comparing the performance of methods for prospective medical product monitoring. Pharmacoepidemiol Drug Saf. 2012 Jun; 21(6):631-9.
Score: 0.122
-
Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiol Drug Saf. 2012 Jul; 21(7):697-709.
Score: 0.122
-
Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther. 2011 Dec; 90(6):777-90.
Score: 0.121
-
Effects of adjusting for instrumental variables on bias and precision of effect estimates. Am J Epidemiol. 2011 Dec 01; 174(11):1213-22.
Score: 0.121
-
Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap. PLoS Med. 2011 Aug; 8(8):e1001075.
Score: 0.119
-
Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic "matrix design". Pharmacoepidemiol Drug Saf. 2011 Jul; 20(7):675-83.
Score: 0.117
-
Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol. 2011 Jun 15; 173(12):1404-13.
Score: 0.117
-
A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011 Jul; 64(7):749-59.
Score: 0.114
-
The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010 Dec 13; 170(22):1968-76.
Score: 0.114
-
The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010 Dec 13; 170(22):1979-86.
Score: 0.114
-
Confounding control in healthcare database research: challenges and potential approaches. Med Care. 2010 Jun; 48(6 Suppl):S114-20.
Score: 0.110
-
NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf. 2009 Dec; 18(12):1134-42.
Score: 0.106
-
Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J. 2010 Mar; 31(5):561-72.
Score: 0.106
-
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009 Jul; 20(4):512-22.
Score: 0.103
-
Effects of prescription coinsurance and income-based deductibles on net health plan spending for older users of inhaled medications. Med Care. 2009 May; 47(5):508-16.
Score: 0.102
-
Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. J Clin Epidemiol. 2009 Dec; 62(12):1226-32.
Score: 0.101
-
Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. J Clin Epidemiol. 2009 Dec; 62(12):1233-41.
Score: 0.101
-
Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications. Clin Ther. 2008; 30 Spec No:1038-50.
Score: 0.093
-
Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information. Med Care. 2007 Oct; 45(10 Supl 2):S158-65.
Score: 0.091
-
Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control. 2007 Jun; 18(5):561-9.
Score: 0.088
-
Performance of propensity score calibration--a simulation study. Am J Epidemiol. 2007 May 15; 165(10):1110-8.
Score: 0.088
-
Propensity Score Calibration and its Alternatives. Am J Epidemiol. 2007; 165(10):1122-1123.
Score: 0.086
-
Propensity Score Calibration and its Alternatives. Am J Epidemiol. 2007; 165(10):1122-1123.
Score: 0.086
-
Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation. 2007 Jan 02; 115(1):27-33.
Score: 0.086
-
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Sep; 54(9):2757-64.
Score: 0.085
-
Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clin Ther. 2006 Jun; 28(6):964-78; discussion 962-3.
Score: 0.083
-
Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol. 2006 Aug; 59(8):819-28.
Score: 0.083
-
Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. 2006 May; 54(5):1378-89.
Score: 0.083
-
A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Clin Pharmacol Ther. 2006 Apr; 79(4):379-88.
Score: 0.082
-
Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006 Mar; 98(3):253-9.
Score: 0.082
-
Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. J Clin Epidemiol. 2006 Jan; 59(1):18-25.
Score: 0.080
-
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006 May; 59(5):437-47.
Score: 0.079
-
Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol. 2005 Aug; 62(8):1242-8.
Score: 0.078
-
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol. 2005 Aug 01; 162(3):279-89.
Score: 0.078
-
Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives. Hypertension. 2005 Aug; 46(2):273-9.
Score: 0.078
-
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol. 2005 May 01; 161(9):891-8.
Score: 0.077
-
Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology. 2005 Jan; 16(1):17-24.
Score: 0.075
-
A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol. 2005 Jan; 58(1):98-102.
Score: 0.075
-
Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. BMJ. 2004 Mar 06; 328(7439):560.
Score: 0.071
-
Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ. 2002 Mar 19; 166(6):737-45.
Score: 0.062
-
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002 Mar 14; 346(11):822-9.
Score: 0.062
-
Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes. Pharmacoepidemiol Drug Saf. 2022 May; 31(5):566-576.
Score: 0.061
-
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2022 01; 175(1):W4-W5.
Score: 0.061
-
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2021 11; 174(11):1528-1541.
Score: 0.060
-
Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA. Diabetes Care. 2021 08; 44(8):1774-1782.
Score: 0.059
-
Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. Diabetes Care. 2021 03; 44(3):826-835.
Score: 0.057
-
Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020 08 25; 370:m2812.
Score: 0.056
-
Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model. Clin Epidemiol. 2020; 12:607-616.
Score: 0.055
-
Improving measurement of binary covariates in claims data: A simulation study. Pharmacoepidemiol Drug Saf. 2020 09; 29(9):1093-1100.
Score: 0.053
-
Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study. Drug Saf. 2019 11; 42(11):1355-1363.
Score: 0.053
-
Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches. EGEMS (Wash DC). 2019 Jul 15; 7(1):27.
Score: 0.052
-
A Case-Crossover-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data. Clin Pharmacol Ther. 2019 07; 106(1):238-244.
Score: 0.050
-
The Case-Crossover Design for Drug-Drug Interactions: Considerations for Implementation. Epidemiology. 2019 03; 30(2):204-211.
Score: 0.050
-
Quantifying bias reduction with fixed-duration versus all-available covariate assessment periods. Pharmacoepidemiol Drug Saf. 2019 05; 28(5):665-670.
Score: 0.050
-
Defining Exposure in Observational Studies Comparing Outcomes of Treatment Discontinuation. Circ Cardiovasc Qual Outcomes. 2018 07; 11(7):e004684.
Score: 0.048
-
Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index. J Gerontol A Biol Sci Med Sci. 2018 06 14; 73(7):980-987.
Score: 0.048
-
Reuse of data sources to evaluate drug safety signals: When is it appropriate? Pharmacoepidemiol Drug Saf. 2018 06; 27(6):567-569.
Score: 0.047
-
Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ. 2018 02 06; 360:k119.
Score: 0.047
-
Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. Pharmacoepidemiol Drug Saf. 2018 04; 27(4):383-390.
Score: 0.047
-
Medication Synchronization Programs Improve Adherence To Cardiovascular Medications And Health Care Use. Health Aff (Millwood). 2018 01; 37(1):125-133.
Score: 0.046
-
Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study. J Comp Eff Res. 2018 01; 7(1):57-66.
Score: 0.046
-
Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis. Drug Saf. 2017 10; 40(10):923-932.
Score: 0.046
-
Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. BMJ. 2016 May 24; 353:i2607.
Score: 0.041
-
Dimension reduction and shrinkage methods for high dimensional disease risk scores in historical data. Emerg Themes Epidemiol. 2016; 13:5.
Score: 0.041
-
Developing alerting thresholds for prospective drug safety monitoring. Pharmacoepidemiol Drug Saf. 2016 07; 25(7):755-62.
Score: 0.040
-
Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med. 2015 Jun; 128(6):653.e7-653.e16.
Score: 0.038
-
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Ann Rheum Dis. 2015 Nov; 74(11):1968-75.
Score: 0.036
-
Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. 2015 Jul; 74(7):1360-7.
Score: 0.036
-
Response letter to Eltonsy and colleagues. J Am Geriatr Soc. 2013 May; 61(5):848-9.
Score: 0.034
-
Confronting "confounding by health system use" in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment. Pharmacoepidemiol Drug Saf. 2012 May; 21 Suppl 2:90-8.
Score: 0.031
-
Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011 Dec 01; 365(22):2088-97.
Score: 0.030
-
The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf. 2011 Jun; 20(6):551-9.
Score: 0.029
-
Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. Am Heart J. 2009 Apr; 157(4):613-9.
Score: 0.025
-
Instrumental variable analysis for estimation of treatment effects with dichotomous outcomes. Am J Epidemiol. 2009 Feb 01; 169(3):273-84.
Score: 0.025
-
Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008 Aug 15; 59(8):1097-104.
Score: 0.024
-
Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies. Am Heart J. 2008 Jul; 156(1):31-6.
Score: 0.024
-
Evaluating uses of data mining techniques in propensity score estimation: a simulation study. Pharmacoepidemiol Drug Saf. 2008 Jun; 17(6):546-55.
Score: 0.024
-
Assessing health state utilities in elderly patients at cardiovascular risk. Med Decis Making. 2006 May-Jun; 26(3):247-54.
Score: 0.021
-
Variable selection for propensity score models. Am J Epidemiol. 2006 Jun 15; 163(12):1149-56.
Score: 0.021
-
Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol. 2005 Oct; 25(5):427-34.
Score: 0.020
-
Suboptimal antidepressant use in the elderly. J Clin Psychopharmacol. 2005 Apr; 25(2):118-26.
Score: 0.019
-
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004 Jul; 148(1):99-104.
Score: 0.018
-
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004 May 04; 109(17):2068-73.
Score: 0.018
-
Use of the case-crossover design to study prolonged drug exposures and insidious outcomes. Ann Epidemiol. 2004 Apr; 14(4):296-303.
Score: 0.018
-
Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med. 2003 Dec 15; 115(9):715-20.
Score: 0.018
-
Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia. Clin Ther. 2003 Jan; 25(1):273-84.
Score: 0.016
-
Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial. Control Clin Trials. 2002 Dec; 23(6):757-73.
Score: 0.016
-
Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol. 2002 Jun; 22(3):236-43.
Score: 0.016
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.